Literature DB >> 1727378

Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.

K Chang1, L H Pai, J K Batra, I Pastan, M C Willingham.   

Abstract

K1 is a monoclonal antibody that reacts with a cell surface antigen (CAK1) found in human mesothelia and nonmucinous ovarian tumors. In this article, the characteristics of the CAK1 antigen have been examined in detail. Using immunofluorescence microscopy, we have found that the CAK1 signal is removed from the cell surface by treatment with proteases or by phosphatidylinositol-phospholipase C, but not by neuraminidase and beta-galactosidase. The phosphatidylinositol-phospholipase C-released material was found to contain the CAK1 antigen which was detected by a competition radioimmunoassay. The phosphatidylinositol-phospholipase C-released CAK1 antigen was examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting and found to be approximately 40 kDa protein. The CAK1-K1 antibody complex remains on the cell surface and is poorly internalized, as shown by an acid wash immunofluorescence internalization assay. An immunotoxin composed of K1 and Lys-PE40, a mutant form of Pseudomonas exotoxin lacking the cell binding domain, was not cytotoxic, supporting the conclusion that the CAK1-K1 antibody complex is not internalized. However, an immunotoxin composed of K1 and native Pseudomonas exotoxin was selectively cytotoxic to cells expressing the CAK1 antigen. This cytotoxicity is due to the fact that domain I of Pseudomonas exotoxin promotes internalization of antigens which are not internalized or bound to antibody alone. Our results suggest that CAK1 is a polypeptide that is expressed on mesothelial cells and many ovarian cancers, and that K1 may be useful as a targeting agent for the immunotherapy of human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727378

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Authors:  Marcela V Maus; Andrew R Haas; Gregory L Beatty; Steven M Albelda; Bruce L Levine; Xiaojun Liu; Yangbing Zhao; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

5.  Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells.

Authors:  C Ballaré; M Barrio; P Portela; J Mordoh
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

6.  Monoclonal antibodies against native ovarian tumor cells: specificity and characterization of the antigen. A preliminary report.

Authors:  L Wasserman; A Neri; B Kaplan; Y Manor; M Galli; B Hardy
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

8.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

Review 9.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

10.  The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.

Authors:  Bei Wang; Janelle M Y Kuroiwa; Li-Zhen He; Anna Charalambous; Tibor Keler; Ralph M Steinman
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.